Dr. Riddell, along with several others physicians and scientists, is a member of the CRI-SU2C Cancer Immunology Translational Research Dream Team, which is performing comprehensive experiments aimed at improving immunotherapy’s ability to improve patient outcomes.
Among the Dream Team’s activities are: systematically assessing the expression of candidate molecules and pathways in the tumor microenvironment before and after checkpoint blockade immunotherapy; using a combination of sequencing techniques to assess checkpoint blockade-induced T-cell responses to tumor-specific neo-antigens; working to improve the quality of cancer-specific T cell generated for adoptive cell transfer (ACT) therapy; evaluating the effect of epigenetic therapy on immunotherapy and assessing the combination of checkpoint blockade immunotherapy and ACT in patients.
Projects and Grants
Immunologic checkpoint blockade and adoptive cell transfer in cancer therapy
Fred Hutchinson Cancer Research Center | All Cancers, Kidney Cancer, Lung Cancer, Melanoma, Prostate Cancer | 2013
¡Hagamos correr la voz sobre la inmunoterapia! Haga clic para compartir esta página con su comunidad.